CRISPR/Cas9 mediated knocking out of OPN gene enhances radiosensitivity in MDA-MB-231 breast cancer cell line

Behbahani, Rahil Ghanbarnasab; Danyaei, Amir; Teimoori, Ali; Tahmasbi, Marziyeh; Neisi, Niloofar

doi:10.1007/s00432-022-04304-7

Cited by 3 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the intracellular form of SPP1 has been detected in 100% of primary CNS tumors [25] and animal models have shown that it increases the invasive capacity of Epstein-Barr virus B cells across the nervous system, including the blood-brain barrier, in neurological diseases like multiple sclerosis [26]. Further, in vitro analysis has demonstrated that SPP1 can also inhibit sensitivity to certain chemotherapeutic agents such as doxorubicin [27,28] and radiotherapy [29], implying that it might adversely impact tumor response.…”

Section: Introductionmentioning

confidence: 99%

Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin’s Lymphoma

De Re,

Lopci,

Brisotto

et al. 2023

Biomedicines

View full text Add to dashboard Cite

The primary objective of this study was to investigate the potential role of tissue osteopontin, also known as secreted phosphoprotein 1 (SPP1), as a contributing factor to an unfavorable prognosis in classical Hodgkin’s lymphoma (HL) patients who received the same treatment protocol. The study involved 44 patients aged 4–22 years, with a median follow-up period of 3 years. Patients with higher levels of SPP1 were associated with tissue necrosis and inflammation, and there was a trend toward a poorer prognosis in this group. Before therapy, we found a correlation between positron emission tomography (PET) scans and logarithmic SPP1 levels (p = 0.035). However, the addition of SPP1 levels did not significantly enhance the predictive capacity of PET scans for recurrence or progression. Elevated SPP levels were associated with tissue mRNA counts of chemotactic and inflammatory chemokines, as well as specific monocyte/dendritic cell subtypes, defined by IL-17RB, PLAUR, CXCL8, CD1A, CCL13, TREM1, and CCL24 markers. These findings contribute to a better understanding of the potential factors influencing the prognosis of HL patients and the potential role of SPP1 in the disease. While the predictive accuracy of PET scans did not substantially improve during the study, the results underscore the complexity of HL and highlight the relationships between SPP1 and other factors in the context of HL relapse.

show abstract

Section: Introductionmentioning

confidence: 99%

Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin’s Lymphoma

De Re,

Lopci,

Brisotto

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

microRNA-944 inhibits breast cancer cell proliferation and promotes cell apoptosis by reducing SPP1 through inactivating the PI3K/Akt pathway

Cui

et al. 2023

Apoptosis

View full text Add to dashboard Cite

Let’s make it personal: CRISPR tools in manipulating cell death pathways for cancer treatment

Bayat,

Nahand

2024

Cell Biol Toxicol

View full text Add to dashboard Cite

Advancements in the CRISPR technology, a game-changer in experimental research, have revolutionized various fields of life sciences and more profoundly, cancer research. Cell death pathways are among the most deregulated in cancer cells and are considered as critical aspects in cancer development. Through decades, our knowledge of the mechanisms orchestrating programmed cellular death has increased substantially, attributed to the revolution of cutting-edge technologies. The heroic appearance of CRISPR systems have expanded the available screening platform and genome engineering toolbox to detect mutations and create precise genome edits. In that context, the precise ability of this system for identification and targeting of mutations in cell death signaling pathways that result in cancer development and therapy resistance is an auspicious choice to transform and accelerate the individualized cancer therapy. The concept of personalized cancer therapy stands on the identification of molecular characterization of the individual tumor and its microenvironment in order to provide a precise treatment with the highest possible outcome and minimum toxicity. This study explored the potential of CRISPR technology in precision cancer treatment by identifying and targeting specific cell death pathways. It showed the promise of CRISPR in finding key components and mutations involved in programmed cell death, making it a potential tool for targeted cancer therapy. However, this study also highlighted the challenges and limitations that need to be addressed in future research to fully realize the potential of CRISPR in cancer treatment. Graphical abstract Current application of CRISPR system in cancer therapy through a glance. A choosing the appropriate biological model for screening in vitro (using established cell lines, animal derived tumor cells, human derived tumor cells, stem cells or T cells), in vivo (using animal models which can harbor human derived tumor), or ex vivo (human/animal-derived organoids). B preparation of CRISPR gRNA library. C experimental design of CRISPR screening, identification of the desired gRNAs or phenotypic response. D CRISPR-Cas targeting of the identified targets, with Cas9 gene editing system (Knockout, base editing, prime editing), RNA modulation (modulation of RNA splicing, RNA base editing, RNA interference), and epigenomic edits and CRISPR interference/activation using dead Cas9 (dCas9) (Bock et al. 2022b)

show abstract

CRISPR/Cas9 mediated knocking out of OPN gene enhances radiosensitivity in MDA-MB-231 breast cancer cell line

Cited by 3 publications

References 32 publications

Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin’s Lymphoma

Preliminary Study of the Relationship between Osteopontin and Relapsed Hodgkin’s Lymphoma

microRNA-944 inhibits breast cancer cell proliferation and promotes cell apoptosis by reducing SPP1 through inactivating the PI3K/Akt pathway

Let’s make it personal: CRISPR tools in manipulating cell death pathways for cancer treatment

Contact Info

Product

Resources

About